Heritage Pharmaceuticals Inc. announced the immediate availability of prochlorperazine edisylate injection in the 5mg/mL strength. This product is the AP rated generic equivalent to the former brand Compazine and adds to Heritage’s growing portfolio of generic injectable prescription products.
According to IMS data for the twelve-months ended December 2013, the US market for prochlorperazine edisylate injection approximated $5.5 million.
Prochlorperazine edisylate injection is indicated for the treatment of severe nausea and vomiting.
Heritage Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacturing, sales and marketing of generic and legacy branded pharmaceutical products for the US prescription drug market.